US Exchange Filings

HCW Biologics’ shareholder vote on approving shares tied to July warrant financing was delayed after its November meeting failed to reach a quorum. Investors will now consider that proposal—and a similar one covering September warrants—at a virtual meeting on January 26, 2027.

HCW Biologics failed to obtain a quorum at a special shareholder meeting on November 17, so stockholders did not vote on a proposal tied to warrants issued in a July private placement. The company has rescheduled that vote for January 26, 2027, and will ask shareholders to consider a second, similar proposal covering warrants from a September private placement.

The proposals concern Nasdaq-required shareholder approval for issuing common shares when the warrants are exercised. Neither proposal was decided at the November meeting.

Key details

  • The November meeting adjourned without conducting business. Not enough shares were present or represented by proxy to form a quorum, so no vote was taken.
  • The first proposal covers July financing warrants. It seeks approval for issuing shares upon exercise of warrants for up to 618,682 common shares, at $2.585 per share. The warrants were issued in connection with a private placement that closed on July 29, 2026.
  • A second proposal will cover September financing warrants. Shareholders will also be asked to approve share issuance upon exercise of warrants from a private placement that closed on September 23. The company did not provide the number of shares or exercise price for those warrants in this announcement.
  • The rescheduled meeting will be held virtually at 10:00 a.m. Eastern time on January 26, 2027. The record date is December 15, 2026.
  • Proxy materials are expected around December 17. HCW Biologics said it plans to file a definitive proxy statement and solicit votes ahead of the meeting.

What changes

The November meeting’s lack of a quorum delayed the shareholder decision; it did not resolve either proposal. The company will now seek approval for both warrant-related share issuances at the January meeting. Approval is being sought to meet Nasdaq listing requirements.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.